PMID- 36941021 OWN - NLM STAT- MEDLINE DCOM- 20230322 LR - 20230414 IS - 2053-8790 (Print) IS - 2053-8790 (Electronic) IS - 2053-8790 (Linking) VI - 10 IP - 1 DP - 2023 Mar TI - Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China. LID - 10.1136/lupus-2022-000819 [doi] LID - e000819 AB - OBJECTIVE: Lupus erythematosus (LE) is a complicated disease with highly heterogeneous clinical manifestations. Previous studies have rarely included all subgroups of patients with lupus and have overlooked the importance of the cutaneous manifestations thereof. We aimed to compare the demographic and clinical differences among patients with different subtypes of lupus. METHODS: This is the first real-world study with a relatively large sample size that simultaneously includes patients with isolated cutaneous lupus erythematosus (iCLE) and SLE. All samples were obtained from the Lupus Erythematosus Multicenter Case-control Study in Chinese populations (LEMCSC) (registration number: ChiCTR2100048939). Comparative analyses between different LE subgroups were performed. RESULTS: A total of 2097 patients with lupus were included, with 1865 patients with SLE, 1648 with cutaneous lupus erythematosus (CLE), and 232 with iCLE. Among the patients with CLE, 1330 had acute cutaneous lupus erythematosus (ACLE); 160 had subacute cutaneous lupus erythematosus (SCLE); and 546 had chronic cutaneous lupus erythematosus (CCLE). The study included a relatively large number of patients with CCLE subtypes, including 311 with discoid lupus erythematosus (DLE), 262 with chilblain lupus erythematosus (CHLE) and 45 with lupus erythematosus profundus (LEP). Demographic characteristics, systemic involvement, mucocutaneous manifestations and autoantibodies were significantly different among the groups. CONCLUSIONS: CLE and iCLE are two distinct disease states, and the selection of broad or narrow CLE definitions should be emphasised in scientific reports. LE-non-specific cutaneous lesions imply more severity, while self-reported photosensitivity and LE-specific cutaneous manifestations imply milder severity. Generalised ACLE appears to be a more severe state than localised ACLE, and CHLE appears to be more severe than DLE. Anti-Sjogren's syndrome-related antigen B (SSB) antibodies have higher specific directivity than anti-Sjogren's syndrome-related antigen A (SSA) antibodies for SCLE lesions. Anti-double-stranded DNA antibodies have a higher co-occurrence with ACLE and a lower co-occurrence with SCLE and CCLE. Compared with DLE, CHLE has significantly higher positive rates of anti-SSA/Ro60 (71%) and anti-SSA/Ro52 (42.4%) antibodies, whereas LEP is associated with a higher positive rate of antinucleosome antibodies (31.1%). CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. FAU - Jin, Hui AU - Jin H AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. AD - Research Unit of Key Technologies of Immune-related Skin Diseases Diagnosis and Treatment, Chinese Academy of Medical Sciences Institute of Dermatology, Nanjing, China. AD - Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China. AD - Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China. AD - Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China. FAU - Zhou, Shihang AU - Zhou S AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. AD - Research Unit of Key Technologies of Immune-related Skin Diseases Diagnosis and Treatment, Chinese Academy of Medical Sciences Institute of Dermatology, Nanjing, China. AD - Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Yu, Yangyiyi AU - Yu Y AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. AD - Research Unit of Key Technologies of Immune-related Skin Diseases Diagnosis and Treatment, Chinese Academy of Medical Sciences Institute of Dermatology, Nanjing, China. AD - Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Zhao, Ming AU - Zhao M AD - Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China. AD - Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China. AD - Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China. FAU - Wu, Haijing AU - Wu H AUID- ORCID: 0000-0002-6338-5089 AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Long, Hai AU - Long H AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Fu, Siqi AU - Fu S AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Wu, Ruifang AU - Wu R AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Yin, Heng AU - Yin H AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Liao, Jieyue AU - Liao J AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Luo, Shuangyan AU - Luo S AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Liu, Yu AU - Liu Y AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Zhang, Qing AU - Zhang Q AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Zhang, Peng AU - Zhang P AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Tan, Yixin AU - Tan Y AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Luo, Shuaihantian AU - Luo S AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Huang, Xin AU - Huang X AD - Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Li, Fen AU - Li F AD - Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Ling, Guanghui AU - Ling G AD - Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Lu, Qianjin AU - Lu Q AUID- ORCID: 0000-0002-4192-4897 AD - Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China qianlu5860@pumcderm.cams.cn. AD - Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China. AD - Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China. LA - eng SI - ChiCTR/ChiCTR2100048939 PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - England TA - Lupus Sci Med JT - Lupus science & medicine JID - 101633705 SB - IM MH - Humans MH - Cross-Sectional Studies MH - Case-Control Studies MH - *Lupus Erythematosus, Systemic/complications/diagnosis/epidemiology MH - *Lupus Erythematosus, Cutaneous/complications/diagnosis MH - *Lupus Erythematosus, Discoid/complications/epidemiology MH - *Sjogren's Syndrome/complications MH - Acute Disease PMC - PMC10030678 OTO - NOTNLM OT - autoimmune diseases OT - lupus erythematosus, systemic OT - lupus nephritis COIS- Competing interests: None declared. EDAT- 2023/03/21 06:00 MHDA- 2023/03/23 06:00 PMCR- 2023/03/20 CRDT- 2023/03/20 20:53 PHST- 2022/08/31 00:00 [received] PHST- 2023/03/02 00:00 [accepted] PHST- 2023/03/20 20:53 [entrez] PHST- 2023/03/21 06:00 [pubmed] PHST- 2023/03/23 06:00 [medline] PHST- 2023/03/20 00:00 [pmc-release] AID - 10/1/e000819 [pii] AID - lupus-2022-000819 [pii] AID - 10.1136/lupus-2022-000819 [doi] PST - ppublish SO - Lupus Sci Med. 2023 Mar;10(1):e000819. doi: 10.1136/lupus-2022-000819.